• Study was performed on 500 urine specimens, making it the largest to date
• Published in Acta Cytologica, a leading cytopathology journal
• Expected to result in increased uptake of Sienna’s hTERT test for routine clinical use
• Article now available on-line at https://www.karger.com/Article/FullText/89181
Melbourne, Australia, 7 June 2018: Sienna Cancer Diagnostics Ltd, (ASX:SDX) (“Sienna” or “The Company”), a medical technology company developing and commercialising innovative cancer related tests, is pleased to announce the results of the largest independent study to date using Sienna’s IVD test, conducted by Johns Hopkins Hospital, have been published in leading cytopathology journal Acta Cytologica.
For further information please download PDF attached:
Download this document
